Research and development investment of more than 7 million, on the drug Xinyi metformin tablets "over-reviewed"

Pharmaceutical Network Enterprise News: Shanghai Pharma announced on the evening of March 16 that the company's wholly-owned subsidiary of the pharmaceutical Xinyi product metformin sultry tablets (0.5g) through the consistency evaluation of generic drugs, the company has invested more than 7 million yuan in research and development costs
Metformin is a hypoglycemic drug, mainly used to improve the sugar tolerance of patients with type 2 diabetes, the product can be used alone or in combination with sulfonynasis or insulin, in order to control the blood sugar of people with type 2 diabetesMetformin hydrochloride tablets were previously developed by Merck and launched in the United States in 1995The drug belongs to the category A varieties of China's medical insurance catalogue (2019 edition) and the basic drug catalogue (2018 edition)IQVIA database shows that the purchase amount of the drug in China's public hospitals in 2019 was RMB147.6 million
The author from the State Drug Administration data query, on the domestic metformin tablets (0.5g) content of 7, related enterprises include The Letter, China and the United States Shanghai Shiguibao, Sichuan Pharmaceuticals, Shipharmaceutical, Kunshan Peili, North China Pharmaceuticals, Zhonglian Pharmaceuticals, etc, it can be seen that the market competition for metformin hydrochloric acid metformin tablets is also quite fierce
At present, metformin hydrochloride (0.5g) through the consistency of the evaluation of domestic enterprises, in addition to the drug xinyi, there are North China Pharmaceuticals, stone medicine, EuropeAmong them, the stone drug European-Italian metformin tablets to the United States ANDA identity transmitted to domestic success, by the "China listed drug catalog" included, as if through the consistency evaluation, specifications of 0.5g and 0.85g, is currently one of the key products of stone drug group blood sugar reduction drugs;
In January 2019, Sinyi applied to the State Drug Administration for the consistent evaluation of generic drugs and accepted itAs of the date of this announcement, the company has invested about RMB 7.252 million in research and development expenses for the drug's consistency evaluationShanghai Pharma did not sell the drug in 2019
In this announcement, The Company said that in accordance with the relevant national policies, through the consistent evaluation of drug varieties in the areas of medical insurance payment and procurement of medical institutions will receive greater support
Therefore, the drug Xinyi's metformin hydrochloride (0.5g) through the generic drug consistency evaluation, is conducive to expanding the market share of the drug, improve market competitiveness, while the company's follow-up products to carry out generic drug consistency evaluation work has accumulated valuable experience
As a large country with diabetes, China has diabetes in almost one in 10 people, and the rising prevalence of the large population base has led to a rapid increase in the number of people with diabetesData show that between 2011 and 2017, the number of adults aged 20-79 with diabetes in China climbed from 0.9 billion to 110 million The number of diabetes in China has increased year by year in recent years due to genetic or environmental factors and the increasing aging The number of people with diabetes is expected to reach 160 million by 2028, according to The Frot s Sullivan Among them, type 2 diabetes is a very common type of diabetes, the prevalence rate jumped from 0.67% in 1980 to 10.4% in 2013, there is still a trend of growth
The industry expects that, in this context, metformin hydrochloride and other related diabetes drugs have a broad market and clinical application prospects With the introduction of more products, will further benefit the diabetes patients drug choice, to help China's development in the field of anti-diabetic, and with more products through consistency evaluation, the market competition is more intense.